Objective: Postmenopausal changes in the hormonal milieu in women with or without hormone therapy are hypothesized to be the pathway for a number of menopause-associated modifications in physiology and disease risk. Physical activity may modify these changes in women's hormone profiles. The crucial yet complex relationship between physical activity and physiologic and pharmacologic sex hormone levels in postmenopausal women has not been investigated sufficiently.
M
enopause results in considerable physical and psychologic changes and has been associated with the risk of cardiovascular disease, breast cancer, and osteoporosis.
1<4 Some of these associations are hypothesized to be related to menopause-associated metabolic and hormonal changes. 5, 6 Although hormone therapy has been the focus of intervention in menopause, its risk-benefit ratio is still debated.
7<9
Low levels of physical activity are associated with elevated cardiovascular disease risk in postmenopausal women, 10, 11 and numerous studies report an inverse association between physical activity and breast cancer risk in postmenopausal women. 12, 13 A plausible mechanism by which physical activity may modulate disease risk is through hormone-related pathways.
14 However, observational studies have yielded inconsistent associations between physical activity and sex hormone levels. 14, 15 The effect of physical activity on endogenous hormone levels in women not using HT versus women exposed to exogenous sex hormones after menopause remains largely unexplored. 15, 16 We used data from the Estrogen in the Prevention of Atherosclerosis Trial (EPAT; clinicaltrials.gov NCT00115024) to determine the association between physical activity and sex hormone levels in postmenopausal women randomized to estrogen therapy (ET) and women randomized to placebo.
METHODS
This study used post hoc data analysis from EPAT, a randomized, double-blind, placebo-controlled trial conducted among postmenopausal women free from preexisting cardiovascular disease. Detailed EPAT methods have been described elsewhere. 17 The trial tested the primary hypothesis that unopposed ET reduces the progression of subclinical atherosclerosis in this population. 17 Potential participants were prescreened by telephone and attended three screening visits 2 to 4 weeks apart to collect baseline data and to determine study eligibility. Eligible women were postmenopausal (serum estradiol G20 pg/mL), 45 years or older, and not current smokers and had a lowdensity lipoprotein cholesterol level of 130 mg/dL or higher. Women were excluded if breast or gynecologic cancer had been diagnosed in the past 5 years or if these cancers were identified during screening; if they had previously used HT for more than 10 years or had used HT within 1 month of the first screening visit; if they had five or more hot flushes daily that interfered with daily activity and precluded randomization; if they had a diastolic blood pressure greater than 110 mm Hg, an untreated thyroid disease, a life-threatening disease with a survival prognosis of less than 5 years, a total triglyceride level of 4.52 mmol/L or greater (400 mg/dL), a high-density lipoprotein cholesterol level less than 0.78 mmol/L (G30 mg/dL), or a serum creatinine concentration greater than 221 mmol/L (92.5 mg/dL); or if they were current smokers. All women, including those with diabetes mellitus, were included provided that their fasting blood glucose level was less than 11.1 mmol/L (G200 mg/dL). A total of 222 women (111 per group) were randomly assigned to the unopposed estradiol or placebo treatment group in one of eight strata defined by low-density lipoprotein cholesterol (G4.15 mmol/L [G160 mg/dL] or Q4.15 mmol/L), previous duration of HT use (G5 y or Q5 y), and having diabetes mellitus (yes or no). Participants were followed every month for the first 6 months and every other month thereafter for 2 years. The study protocol was approved by the institutional review board of the University of Southern California; all participants gave written informed consent. 17 
Sex steroid hormones
Before randomization and every 6 months during trial follow-up, fasting blood was drawn; serum was stored at j70-C. Sex hormone levels were measured from stored samples. All samples for each participant were processed in the same batch. Radioimmunoassay was used to quantify the serum levels of androstenedione, dehydroepiandrosterone (DHEA), testosterone, estrone, and estradiol. Before undergoing radioimmunoassay, steroids were extracted from serum using hexane-ethyl acetate (3:2). Androstenedione, DHEA, total testosterone, estrone, and estradiol were then separated using Celite column partition chromatography. 18 The sex hormoneYbinding globulin (SHBG) was quantified through direct immunoassay using the Immulite analyzer (Diagnostic Products Corporation, Inglewood, CA). Free testosterone and free estradiol were calculated using total testosterone and total estradiol concentrations, respectively, SHBG concentrations, and an assumed constant for albumin in a validated algorithm. 19 Intra-assay and interassay coefficients of variation ranged from 4% to 8% and 8% to 13%, respectively. The assay sensitivities for estradiol, estrone, testosterone, DHEA, androstenedione, and SHBG were 3 pg/mL, 4 pg/mL, 1.5 ng/mL, 0.04 ng/mL, 0.03 ng/mL, and 1 nmol/L, respectively.
Assessment of physical activity
The Stanford Seven-Day Physical Activity Recall was completed at baseline and every 6 months. 20 This questionnaire is a self-report recall instrument assessing physical activity during the previous week. 21 Each reported activity was coded for its metabolic equivalents of energy expenditure (METs) using the coding scheme provided by Ainsworth et al. 22 For each week recalled, the energy expenditure of each activity was calculated by multiplying the number of hours of participation by the activity's MET. Any self-reported activity that required three to six METs was considered to be of moderate intensity, and any that required more than six METs was considered a vigorous-intensity physical activity. Energy expenditure in sleep was calculated by multiplying the sleep time by 1 MET. Time spent in light activity was computed by subtracting the sum of the time spent in sleep and in doing moderate and vigorous activity from the total 168 weekly hours. The metabolic cost of light activity was computed by multiplying the number of hours spent in light activities by 1.5 MET. 23 Total energy expenditure was the sum of energy expenditure (METhours) in sleep and in doing light, moderate, and vigorous activities.
Other reproductive and anthropometric measures
Reproductive and smoking history and demographic factors including age, race, income, and education were assessed by structured questionnaires completed at baseline. Reproductive history included age at menarche, age at last menstrual period, and history of hysterectomy and oophorectomy. For women without a hysterectomy/oophorectomy, the age at last menstrual period was considered their age at natural menopause. For women with bilateral oophorectomy, age at surgery was considered the age of menopause. For 15 participants with hysterectomy and unilateral oophorectomy and 26 participants with hysterectomy without oophorectomy, the mean age at natural menopause of the sample was imputed as their menopause age. Menopause status was validated by the levels of serum estradiol (less than 20 pg/mL). Height and weight were measured using a free-standing stadiometer and a calibrated digital scale (Salter) to the nearest 0.1 cm and 100 g, respectively. Body mass index (BMI) was calculated as weight (in kilograms) divided by the square of height (in meters).
Statistical analysis
This post hoc analysis included 104 of 111 participants in the placebo group and 90 of 111 participants in the estradiol group who had data available for both physical activity and hormone levels. Demographic characteristics between the treatment groups were compared using independent t tests (means) or W 2 tests (proportions). Baseline and average ontrial levels of sex hormones were compared between the treatment groups using independent t tests. Because total estradiol and estrone levels were not normally distributed, these variables were log-transformed for analysis and backtransformed for summarizing results.
We computed the average value (averaged in the course of the trial) of each sex hormone, SHBG, and physical activity levels for each participant. Therefore, each participant contributed one observation to the analysis. All measurements (baseline and on-trial) were used to calculate the per-participant means of sex hormones and SHBG for the placebo group. For the estradiol-treated group, only the on-trial measurements were used to calculate these per-participant means. Because the assessment of physical activity in EPAT began nearly a year after the initial participant recruitment, a number of participants did not have baseline physical activity data (71 in the placebo group and 68 in the estradiol group). All available measurements (baseline and/or on-trial) were used to calculate the perparticipant means of physical activity for both placebo-and estradiol-treated women.
The serum levels of the different sex hormones and SHBG were modeled separately as continuous variables in all analyses. Within each treatment group, we fitted general linear models to assess the continuous relationship between average physical activity and average sex hormone levels. An analysis of variance was used to compare the means of hormone levels across categorical levels of physical activity. We also tested for a trend in average hormone/SHBG levels across categories of physical activity by fitting the median value for each physical activity category.
We modeled physical activity in different ways to assess the qualitative and quantitative associations with hormone levels. Total weekly MET expenditure (total MET-hours) was the sum of energy expenditure as detailed previously; total MET-hours was modeled as a continuous variable and as a categorical variable (four quartiles of total MET-hours). Physical activity was also modeled as total time (in hours per week) spent in physical activity of moderate intensity or higher (total hours spent in activities with MET estimates 3 or greater) and hours per week spent in vigorous-intensity physical activity (total hours spent in activities with MET estimates greater than 6). Time in moderate or vigorous physical activity was categorized into three levels based on the tertile distribution of the total sample. Time in vigorous physical activity was also categorized into three levels; the lowest levels represented women reporting no vigorous activity, whereas the upper two levels were determined using a median split of weekly hours of vigorous activity (among participants reporting at least one vigorous activity).
Hormone and SHBG levels were initially modeled as dependent variables without covariate adjustment. The age at randomization, race, BMI, age at menopause, type of menopause (natural, surgical), smoking status (ever, never smoked regularly), and years since menopause were evaluated as possible confounders. Confounding was assessed by comparing the unadjusted to the covariate-adjusted change in the A estimate (15% or more) of the main effect of physical activity. Wald tests were used to assess the possible effect modification by these covariates, testing product interaction terms in the multivariate model. Because of the high correlation between age at randomization and age at menopause (r = 0.86), we included only age at randomization in the multivariate analyses. Smoking status and years since menopause were not included in the multivariate model because neither variable altered the impact of physical activity on sex hormones. None of the interaction tests were statistically significant (all P 9 0.10). Our final models included adjustment for age at randomization, race, BMI, and type of menopause. All statistical analysis used SAS software 9.13 (SAS Inc., Cary, NC), and all tests for significance were conducted at a two-sided 0.05 level.
RESULTS

Baseline characteristics
The baseline characteristics of the 194 participants included in the analysis are summarized in Table 1 . Compared with placebo recipients, more estradiol recipients had a history of hysterectomy or surgical menopause (P = 0.03). The groups did not significantly differ in other demographic and reproductive characteristics. The physical activity levels were generally comparable between the treatment groups. However, estradiol-treated women spent more time in vigorous physical activity than did placebo-treated women (P = 0.04). Treatment group comparisons on hormone levels Women in the placebo and estradiol groups had different levels of estrone at baseline (P = 0.02) but were comparable in all other hormone levels ( Table 2) . During the trial, the estradiol group had statistically significantly higher mean levels of estradiol, estrone, bioavailable estradiol, free estradiol, and SHBG and statistically significantly lower mean levels of bioavailable and free testosterone (P G 0.001 for all) and DHEA (P = 0.02) than did the placebo participants.
Associations of physical activity with sex hormone levels (placebo-treated group)
The relationships between average total weekly MET expenditure and hormone and SHBG levels among the 104 placebo-treated women are summarized in Table 3 . Adjusting for age at randomization, race, BMI, and type of menopause, continuous measures of total energy expenditure were positively associated with SHBG levels (P G 0.001) and inversely associated with total testosterone (P G 0.001), bioavailable testosterone (P G 0.001), free testosterone (P G 0.001), androstenedione (P G 0.001), bioavailable estradiol (P = 0.02), and free estradiol (P = 0.02). The results analyzed by quartile of total energy expenditure were consistent with the continuous analysis.
The amount of time spent in physical activity of moderate or higher intensity among the placebo group participants was statistically significantly positively associated with SHBG level (P G 0.001) and was inversely associated with the serum levels of total testosterone (P = 0.006), bioavailable testosterone (P G 0.001), and free testosterone (P G 0.001; Table 4 ). Only 36% of the placebo participants reported some time spent in vigorous physical activity; only 9% reported more than 1 hour of vigorous activity on average per week during the trial period. The relationships of hormone levels with vigorous physical activity as a continuous measure and in three categories (0 weekly hours, up to 0.3 weekly hours, more than 0.3 weekly hours) are summarized in Table 5 . All continuous and categorical measures of testosterone (total, bioavailable, and free) were statistically significantly inversely associated (all P G 0.001), whereas serum DHEA level was positively associated (P = 0.002) with the time spent in vigorous physical activity. SHBG levels were positively associated with vigorous physical activity only when analyzed on a categorical scale (P = 0.04). The mean (SD) SHBG level was 33.0 (1.3), 39.4 (1.9), and 39.0 (2.1) nmol/L for women with no vigorous physical activity, with up to 0.3 weekly hours of vigorous activity, and with more than 0.3 weekly hours of vigorous activity, respectively.
Associations of physical activity with hormone levels (estradiol-treated group)
The relationships between total weekly MET expenditure and hormone and SHBG levels in 90 estradiol-treated women are summarized in Table 3 . None of the hormones or SHBG levels were statistically significantly associated with the continuous measures of total weekly energy expenditure after adjustment for age at randomization, race, BMI, and type of menopause. However, total estradiol level decreased with increasing quartiles of energy expenditure (P = 0.04). There was evidence of decreasing trends in bioavailable estradiol and free estradiol levels, although these associations did not achieve statistical significance (P = 0.06 for both). The associations of total MET quartiles with other hormones were consistent with continuous analyses.
Total estradiol (P = 0.001), bioavailable estradiol (P = 0.01), and free estradiol (P = 0.01) levels were inversely associated with the continuous measure of weekly hours spent in physical activity of moderate or higher intensity (Table 4) . Androgen levels were not statistically significantly associated with the number of hours spent weekly in moderate or vigorous activities. Serum DHEA (P = 0.001) and androstenedione (P = 0.005) levels increased with the increasing tertiles of time spent in moderate or vigorous activity.
Relationships of the hormones to vigorous physical activity, defined as continuous and categorical measures, are summarized in Table 5 . All estrogen measures were inversely associated with the amount of time spent in vigorous physical activity (P G 0.001-0.01), whereas mean DHEA was positively associated with time spent in vigorous physical activity (P G 0.001). Serum androstenedione levels were inversely associated with time in vigorous physical activity only when analyzed in the three categories of vigorous physical activity.
DISCUSSION
In this cohort of postmenopausal women participating in a randomized controlled clinical trial, physical activity levels were associated with sex steroid hormone levels in both placebo-and estradiol-treated women. Among the estradioltreated women, total energy expenditure on a continuous scale was not associated with alterations in any hormone or SHBG level. However, in a categorical analysis, estradiol levels decreased with increasing quartiles of total energy expenditure. All measures of serum estradiol were inversely associated with the total hours spent in moderate or vigorous physical activity. There was also a statistically significant increasing trend in serum DHEA and androstenedione level, with increasing tertiles of weekly hours spent in moderate or vigorous physical activity. Among the placebo-treated women, the total energy expenditure was inversely associated with circulating concentrations of most androgens and bioavailable and free estradiol. The total number of hours spent in physical activity of moderate or higher intensity, as well as the time spent in vigorous physical activities, was negatively associated with all measures of serum testosterone. SHBG was positively associated with total energy expenditure and the amount of time spent in moderate and vigorous activity. Most of our findings are consistent with the results from other studies. 14,24<26 Although the relationship between physical activity and sex hormone levels in postmenopausal women taking exogenous female steroid hormones is a crucial topic, there exists a paucity of data. Our EPAT data represent the first report on the relationship between physical activity and sex hormone levels in postmenopausal women taking estradiol or any exogenous female steroid hormones. The statistically significant inverse trend of female sex hormones with increasing time spent in moderate or vigorous physical activities may be beneficial in the presence of an added risk of breast cancer associated with ET in some studies. 8, 27, 28 These observations associated with ET are consistent with and extend previously reported relationships between physical activity and endogenous estrogen levels.
29<32
A reduction in female sex hormones with higher physical activity may affect breast cancer risk in postmenopausal women. High endogenous estrogen levels are associated with elevated breast cancer risk in postmenopausal women. 28 Cumulative exposure to estrogen is particularly relevant to breast cancer risk and is determined by factors such as age at menarche, age at menopause, pregnancy, lactation, and postmenopausal obesity.
1 Physical activity itself has been associated with reduced breast cancer risk. Numerous reports have investigated the relationship between physical activity and breast cancer risk, 9 out of 10 studies reporting separately for postmenopausal women, found an inverse association. 29 The mechanisms by which physical activity exerts its beneficial effects are still being explored and debated.
30<32
The direct association of physical activity with serum SHBG levels may also have implications for reduced breast cancer risk. SHBG binds estradiol, reducing the bioavailability of this hormone. Postmenopausal women with low serum SHBG levels have increased risk of breast cancer. 14 The statistically significant negative associations of physical activity with androgens in the placebo group may imply a beneficial effect on cardiovascular disease. A large body of observational evidence suggests a positive association between menopause and cardiovascular disease risk. 33, 34 Some studies suggest that an increase in androgens relative to estrogen in healthy postmenopausal women is associated with an unfavorable cardiovascular risk profile. 35 In EPAT placebo-treated women, androgen levels were affected by as little as 2 hours of moderate or vigorous physical activity per week, which might be explained partially by the positive association of physical activity with serum SHBG. SHBG is known to regulate the concentration of bioavailable estrogen and androgens and has a greater affinity for androgens, especially testosterone. 36 Therefore, physical activity may benefit postmenopausal women not taking any hormonal intervention by contributing to a reduction in androgen excess.
Most of our other findings on nonYhormone users are consistent with much of the current literature. 14, 32 The first randomized controlled trial to address the relationship between physical activity and endogenous sex hormone levels in postmenopausal women investigated the effects of a 12-month moderate-intensity physical activity intervention compared with the effects of performing only stretching exercises (control group). 25, 26, 37 After 3 months, exercisers (n = 87) experienced statistically significant declines in estrone, estradiol, and free estradiol compared with the controls (n = 86). At 12 months, the direction of effect remained the same, although the differences were no longer statistically significant. 26 In addition, at 12 months, women in the exercise intervention group showed reductions in total testosterone and free testosterone compared with the control intervention group. However, the associations were statistically significant only in women who lost more than 2% of body fat. The trial also noted a statistically significant increase in SHBG levels in the moderate exercise intervention group at 3 months; however, this was not maintained at 12 months.
In a recent cross-sectional population-based study, 2,082 postmenopausal women not using exogenous hormones demonstrated inverse relationships between usual physical activity levels and circulating concentrations of estradiol and testosterone.
14 Consistent with our findings, physical activity was also positively associated with SHBG concentrations.
14 Another cross-sectional study on 806 postmenopausal women reported a similar inverse association between estradiol levels and physical activity and a positive association between physical activity and SHBG. 38 In a longitudinal study following participants for 8 years, endurance-trained postmenopausal women had lower estrogen, specifically estrone levels, compared with sedentary women. 39 
Strengths and limitations
There are several strengths of the current analysis from EPAT. This post hoc analysis was performed in the setting of a randomized trial of HT, separately examining women taking exogenous estradiol and women without any exogenous hormones. Therefore, we had a unique opportunity to observe the influence of physical activity in postmenopausal women at both physiologic and pharmacologic levels of hormones, free of selection biases associated with self-selected hormone use. A comprehensive panel of hormones was measured, enabling us to investigate a large part of the hormonal milieu in these postmenopausal women. Moreover, repeated measures of hormone and physical activity allowed us to obtain a more representative measure of a woman's average hormone and physical activity profiles over time than did a single measurement.
The major limitation of the study is the post hoc nature of the analysis, in that EPAT was not designed to address the relationship of physical activity with sex hormone levels in postmenopausal women randomized to ET versus placebo. Therefore, physical activity was not a study intervention but rather represented self-selected activities. We also could not assess longitudinal changes in physical activity because no recommendations were made regarding physical activity; in fact, physical activity remained quite stable during the trial (within-participant coefficient of variation was 2.6% in placebo-treated and 3.7% in estradiol-treated participants).
The relatively small sample size may have compromised our statistical power in testing physical activity and hormone associations. For example, of the 90 participants receiving HT, there were marginally statistically significant decreasing trends in bioavailable and free estradiol levels with increasing quartiles of total energy expenditure. In addition, the small sample reduced the statistical power to test interactions, including possible interactions with BMI and race. The cohort had a high BMI with a mean of 29 kg/m 2 . Because adipose tissue is a major source of estrogens in postmenopausal women, the amount of physical activity might not have been sufficient to reduce the hormones to a great extent in this relatively overweight population of postmenopausal women. This may explain the lack of inverse association of serum levels of estradiol and estrone with the amount of time spent in moderate or vigorous activity in the placebo group, of which only 36% of the participants reported some time spent in vigorous physical activity and only 9% reported more than 1 hour of weekly vigorous physical activity.
CONCLUSIONS
This study adds to the limited evidence on the relationship between physical activity and sex hormone levels in postmenopausal women. The reduction in physical activity with increasing age and/or increasing weight in postmenopause can potentially affect sex hormone levels, contributing to increased disease risks. Given the fact that this was a post hoc crosssectional analysis, we cannot infer a causal relationship between physical activity and hormone levels. Despite that, the implications of the results warrant further exploration. To our knowledge, no study has examined the relationship of physical activity with such a large panel of hormones at both physiologic and pharmacologic states. Further longitudinal interventional studies with a larger sample size might help to further understand the uncertain, largely unexplored yet intriguing relationship between physical activity and sex hormone levels in this population.
